Condition
GM1 Gangliosidoses
Total Trials
3
Recruiting
1
Active
1
Completed
0
Key Insights
Highlights
No notable highlights available yet
Clinical Risk Assessment
Based on trial outcomes
High Risk
Score: 80/100
Termination Rate
33.3%
1 terminated out of 3 trials
Success Rate
0.0%
-86.5% vs benchmark
Late-Stage Pipeline
33%
1 trials in Phase 3/4
Results Transparency
0%
1 of 0 completed with results
Key Signals
1 with results0
Data Visualizations
Phase Distribution
2Total
P 1 (1)
P 4 (1)
Trial Status
Not Yet Recruiting1
Recruiting1
Terminated1
Clinical Trials (3)
Showing 3 of 3 trials
NCT07479953Phase 1Not Yet RecruitingPrimary
Prenatal Intravenous Gene Transfer With an AAV9 Vector Expressing Human Beta-galactosidase in Type I and Type II GM1 Gangliosidosis Clinical Trial
NCT03333200Recruiting
Longitudinal Study of Neurodegenerative Disorders
NCT02030015Phase 4TerminatedPrimary
Synergistic Enteral Regimen for Treatment of the Gangliosidoses
Showing all 3 trials